Corporate Social Responsibility

As a global leader in pharmaceuticals we take pride not only in providing products that
enable people to live healthier and fuller lives, but also in giving back to the society.At
Ranbaxy, Corporate Social Responsibility and concern for Environment, Health and
Safety are a part of the corporate DNA.
Our CSR commitment is a manifestation of our determination to improve the quality of
life for the community at large. Over the years Ranbaxy has ensured that its
environmental footprints are minimal. Our concern for environmental safety is
superseded only by our commitment to enhance employee and community safety.
Being an innovation led pharmaceutical company, we encourage scientific endeavours
through Ranbaxy Science Foundation that offers annual Research Awards aimed at
recognizing and rewarding excellence in original research work.

Profile

Ranbaxy has a strong element of Corporate Social Responsibility

inscribed in its values and its concern for the society extends well
beyond its business motives.

The company does not view success and achievements in terms of commercial gains only
but firmly believes that corporate social responsibility is the key for providing a deep
symbiotic relationship that exists between the company and the environment it functions.
Over two decades ago, in 1979, in the wake of grim health scenario of India, Ranbaxy
realised the urgency to reach out to those who had little or no access even to basic health
care and instituted ‘Ranbaxy Rural Development Trust’.

The main objective of the programme was to deliver primary health care to the
underserved and underprivileged section of the society to achieve positive health for them
and thus to contribute to the national objective ‘Health For All’. As the scope of the
programme and company’s commitment grew, in 1994, a professionally managed,
nonprofit, independent body ‘Ranbaxy Community Health Care Society’ (RCHS) was
established against the backdrop of full moral and financial support of the company.

Community participation

It was recognized that over 70 percent of the deliveries in RCHS

service areas were conducted at home by either untrained or
improperly trained ‘dais'. On one hand, lack of skills was causing many
neo-natal deaths while on the other these ‘dais' acted as counselors to
pregnant women and enjoyed easy accessibility and acceptability.
Thus, as a strategy, two-phase intervention was planned where the
RCHS Medical officers were trained to train the ‘dais' in the first phase
and training of ‘dais' from the community was done in the second
phase.

RCHS has established community based local groups like health committees, women
groups and other interactive groups like “dais”, “anganwari” workers, volunteers,
adolescents and breast-feeding support groups to promote community involvement and
self-sustainability.

Scientific approach

RCHS firmly believes in a focused and integrated approach to the basic

issues of health care that are elementary and directly responsible for
the state of community health in RCHS service areas. With a view to
plan future strategies for need based interventions, RCHS regularly
monitors and records all vital events such as live births, infant deaths,
maternal deaths and abortions etc. For example, the main causes of
infant and maternal mortality as identified in RCHS areas are Low Birth
Weight, Diarrhoea, Pneumonia, Birth Asphyxia, Hypothermia, Anaemia
in pregnancy including obstetrical causes like Sepsis or Haemorrhage.
Special attention is given to promote ORS in Diarrhoea and early
diagnosis and appropriate treatment of Pneumonia. Focussed work
with precise risk groups like pregnant women, lactating mothers,
newly married eligible couples and adolescent girls to prevent low birth
weight and anaemia in pregnancy, including referral services for
dealing with obstetrical emergencies are some of the steps taken in
order to bring down the infant and maternal mortality rates in RCHS
areas.

Road ahead ...

In the future there are plans to develop more need-based programs

with emphasis on educating and empowering communities through
knowledge, access to information and provision of quality services. The
aim remains to improve their quality of life and achieve sustainable
human development.

Ranbaxy Science Foundation

Ranbaxy Laboratories Limited incorporated Ranbaxy Research

Foundation in 1985 and was later reconstituted as a separate society
as Ranbaxy Science Foundation and registered under the Societies Act
in May 1994. with an implicit mission of giving impetus to research
activity and help in reviving India’s great scientific tradition. The
Foundation instituted Ranbaxy Research Awards to recognize original
outstanding contributions in the fields of Medical and Pharmaceutical
Sciences. Every year the Foundation invites nominations for 4 awards
– 3 Awards for Rs. 1,00,000/- each in the fields of Medical Sciences in
Basic. Applied and Clinical and 1 Awards of Rs. 1,00,000/- in the field
of Pharmaceutical Sciences. So far 104 scientists have been honoured
by the Foundation.

Ranbaxy Science foundation (RSF) is a non profit organization

dedicated to promote scientific endeavours in the country by
encouraging and rewarding and channeling national and international
knowledge and expertise on subjects connected with treatment of
diseases afflicting mankind. To achieve these objectives, the
Foundation conducts Round Table Conferences on topics concerning
public health and symposia on topics at the cutting edge of research in
medical sciences to explore the latest in the selected area of specialty
and its potential application for the benefit of mankind.

Being committed to recognising and furthering excellence, the

Foundation has also initiated “Research Scholarship Awards for the
Young Scientists” with an aim to stimulate their interest in research.

Late Prof. V. Ramalingaswami, was the founder Chairman of the

Foundation.

Environment, Health and Safety

Ranbaxy is fully committed to achieve Environment, Health & Safety (EHS) excellence
and conduct its activities in the most responsible manner. Over the years, importance of
EHS has been stressed and extensively promoted as a corporate culture within Ranbaxy.
It is also clearly reflected and well defined into Ranbaxy’s value statements of
“Managing our operations with high concern for safety and environment” and “Be a
responsible corporate citizen”.

Thinking and working responsibly so that the employees, the community at large, and the
environment including the natural resources, are protected leaving minimal
environmental footprints, is integral to Ranbaxy’s EHS philosophy. On the road to EHS
excellence, Ranbaxy has adopted a top down approach and embraced the principles and
codes of best EHS practices into its redefined world class EHS Management System.

Anti Malaria Project

Ranbaxy's Anti-Malaria collaborative research program on Track

Ranbaxy has been working on the anti-malaria collaborative research project since May
2003. Although antimalarial drugs have a large market, it is a market with very limited
resources. Together with the challenges of drug resistance, poor health systems, lack of
affordable, safe and convenient treatment options, malaria treatment represents one of the
largest unmet medical needs. Ranbaxy is developing an synthetic peroxide antimalarial
drug in order to address this unmet need. The company has commenced Phase-III clinical
trials for this drug in India, Bangladesh and Thailand.

Ranbaxy is committed to developing a drug that is not only safe and effective, but also
affordable to people in India, Africa and other disease endemic countries.
Ranbaxy- meeting an unmet need in the neglected disease segment
Ranbaxy Laboratories Limited, the largest pharmaceutical company in India, and
presently ranked among the top ten global generics companies, is building its capacity as
a research-based healthcare company. Based in a malaria endemic country, Ranbaxy
deeply identifies with the continuing crisis that pandemics like malaria are causing in
developing countries. The Company has therefore committed its expertise in R&D to
work towards a breakthrough in the treatment of this important disease.

Challenges in development of new treatment for malaria

Between 1975 and 1999, only four of the almost 1,400 new drugs developed worldwide
were antimalarial, and all were at least in part the products of publicly funded research
Significant R & D effort and funding required to develop new treatments
Returns on the R & D investment are lacking- as the purchasers of the treatment are the
poorest countries around the world. Low cost is essential to ensure wide-spread up-take
Distribution of the treatment is difficult due to the remoteness of the areas in which the
disease is most prevalent and poor health systems in malaria endemic countries

Background
Malaria is one of the most persistent and deadly diseases, claiming the lives of more than
one million people every year. The majority of its victims are children under the age of
five and pregnant women in developing countries.
Malaria is a major public health problem in more than 90 countries inhabited by more
than 2.4 billion people – 40% of the world’s population. The disease is estimated to kill a
child every 30 seconds and to cause up to 600 million new infections worldwide
annually.
Though the majority of the cases and approximately 90% of the malaria deaths are found
in sub-Saharan Africa, the disease is now increasing in Asia and Latin America.

Concerns in the Existing Treatments for Malaria

There are more people dying of malaria today than 30 years ago. The main cause of the
resurgence is drug resistance.

Rising resistance to antimalarial drugs

Universal Chloroquine resistance to Plasmodium falciparum
Development of resistance not only compromises the efficacy of existing antimalarial drugs
but also threatens to pre-maturely terminate the useful therapeutic life of new antimalarial
drugs
Lack of effective, affordable and appropriate treatment options

Anti HIV/AIDS

Ranbaxy comprehensive anti-HIV portfolio comprises Bio-Equivalent Anti-

Retrovirals (ARVs) and Anti-Infectives for Opportunistic infections

Ranbaxy, in its endeavor to make ARVs accessible to patients around the world, is
leveraging its global network of offices, affiliates, joint ventures and alliances. With
Ranbaxy products being marketed in over 125 countries and ground operations in 46
countries, Ranbaxy provides pre & post sales support to institutions, NGOs, and
Ministries of Health, making Ranbaxy ARVs available in their respective treatment
programs Several humanitarian and government programmes have sourced ARVs from
Ranbaxy. Some of them being MoH-Nigeria, MSF in various countries, MDM-
Cambodia, MEDS in Kenya, etc. In Zambia, the Ministry of Health has lauded Ranbaxy's
initiative in making available quality ARVs at reasonable prices in that country. In Latin
America, Ranbaxy's ARVs have been registered in Brazil, Peru, Venezuela and
Guatemala among other countries. In South East Asia, ARVs are being marketed in
Vietnam, Cambodia and Myanmar already. Besides, regulatory filings are on in several
countries in these regions.
Encouraged by the positive response to its efforts to make quality anti-HIV generics,
Ranbaxy is committed to working on all possible fronts and seeking partnerships to
improve access to these medicines.

Ranbaxy offers a complete basket of pharmaceuticals for several first line HAART
regimens. The current portfolio is the largest range of bio-equivalent generic ARVs
available from a single company. These products are manufactured at Ranbaxy's WHO
prequalified and USFDA approved facilities.

• Several Ranbaxy ARVs approved by USFDA and WHO

• First Asian pharmaceutical company to get approval for a generic ARV from
USFDA

• Over 250 approvals of ARVs across 40 countries, with 130 more in pipeline

• Only company using both WHO & USFDA approved API supplier

• Bioequivalence studies conducted at leading CROs in North America

• All ARVs comply with Zone IV and Zone II stability requirements

• Leading supplier of ARVs to global NGOs, Institutions & Government programs

• Ranbaxy's ARVs have catered to treatment programs in over 50 countries globally

• Ranbaxy's quality FDCs reduce pill burden and improve patient compliance

Cipla Ltd.
Sales (2007-2008) =Rs. 4200 crores (rounded off)
Net profit after tax =Rs. 700 crores (rounded off)
CSR Budget= Not Available
Karmayog 2008 CSR Rating: 2/ 5
CSR activities:
As in the past, Cipla has made a special effort to produce this report at a low cost, without
compromising its quality or contents leading to a saving of Rs. 44 lakhs. This amount is
being donated to the Cipla Cancer and AIDS Foundation/Cipla Public Charitable Trust.
Cipla Palliative Care Centre
Cipla Palliative Care Centre started the day care centre in its second year. It serves to
meet the needs of patients who have returned home and have come for follow-up visits
Home vists –
The Centre has home care teams which meet patients at home and train relatives in
 palliative care. Each team, comprising of a doctor, a nurse, a social worker and a
volunteer, caters to patients within a radius of 60 km of the Centre
. An ambulance donated by Rotary International covers this distance.
This experience of a home visit helps us understand facets of the patients better-
like psycho-social background, relationships and more.
Though there is always a dearth of personnel who can go on these home care visits,
generous volunteers have helped the service gain momentum.
Physiotherapy-
As physiotherapy plays an important role in improving the mobility and comfort level of
patients, a specialised unit with a trained physiotherapist, has been instituted at the centre.
The centre has a separate physiotherapy department. Services offered here include
therapy for lymphoedema.
Teaching Palliative Care-
The science of taking care of the terminally ill through palliative care does not yet
form part of the medical curriculum in our country. Although there are a few
institutions doing some very good work, the task ahead is enormous, considering
that cancer alone adds seven lakh terminal patients every year.
If one were to count the unfortunate victims of other diseases too, the magnitude of
the problem will become a little more apparent. While a lot remains to be done to
reach even basic curative care to millions, extending palliative care is an even
more complex task.
One way to begin is to try and teach palliative care to as many doctors, nursing
personnel and socio-medical workers from all over the country. This is the
primary aim behind The Dr K A Hamied Institute for Education and Research in
Palliative Care Science set up by the Cipla Foundation.
The Institute was inaugurated on October 31, 1998, the birth centenary year of Dr K
A Hamied, the founder of Cipla Ltd. Dr V D Karad, well known educationalist
and UNESCO Chair Holder for Peace, Democracy and Human Rights, unveiled
an artist's perspective of the proposed Institute building to mark the launch.
Principal Bal Gadgil, Vice President of Symbiosis Centre, Pune was special Guest
of Honour at the function. Dr Y K Hamied, Chairman and Managing Director of
Cipla Ltd. and N A Raje, Managing Trustee of the Cipla Foundation were present
on the occasion.

Cipla, another Indian pharma major has found a novel approach to fulfill its corporate
social responsibility obligations by offerering to sell a cocktail of three anti-HIV
drugs, Stavudine, Lamivudine and Nevirapine, to the Nobel Prize-winning
voluntary agency Medicine Sans Frontieres (MSF) at a rate of $350, and at $600
per patient per year to other NGOs over the world. This
 offer has to led to an significant decrease in the prices of these drugs worldwide
increasing the accessibility of these drugs especially in the developing countries.

The conception of corporate social responsibility (CSR) is inimitably coupled to a

country's identity in which it primarily operates and therefore, the resulting policies and
programs of CSR are inherently tied to the distinct social, political and economic systems
in which the company operates. How, therefore, does this impact the emergence of CSR
in pharmaceutical companies and is it possible that the convergence of CSR initiatives
into a global standard may be potentially detrimental to countering the spread of
HIV/AIDS?Description: This project looked to examine how Western and Eastern
ideologies of CSR have surfaced within Merck & Co., Inc. and Cipla (India), respectively
and attempted to assess the extent to which a convergence towards a global standard is
present or whether CSR is inherently tied to the unique cultural context in which each
enterprise operates (divergence theory). Lessons learned: The convergence of CSR
polices within the pharmaceutical industry will hamper the diversity of programs needed
to attend to the various levels of HIV/AIDS prevalence in differing countries. The
homogenization of institutional pharmaceutical standards to cope with disease will only
seek to alienate cultural perspectives and deter future progress. Heterogeneity amongst
companies and their response to the AIDS pandemic is critical in assuring that the needs
of disparate groups are met. In fact, this culturally driven, socio-economic response is
integral to the continued success of diversified corporate endeavors and also represents
that a one-size-fits-all approach (a universalized standard) to CSR may negatively impact
the eradication of HIV/AIDS. Recommendation: Pharmaceutical companies must work to
expand their notions of CSR, while striving to better evaluate and improve the impact
their businesses have on human development. Companies must also continue to embrace
the cultural paradigms of the surrounding nation state in order to better address the long
term needs of both the immediate and global communities.

Zydus Cadila
CSR activities:
Zydus School for Excellence-
The purpose of such an institution was to create a fountainhead where children had an
opportunity to broaden the knowledge and the freedom to explore their creative impulses.
Health camps :
Zydus Cadila organises annual healthcare camps at Moraiya, a village adjacent to its
plant premises.
So far, general diagnostic, dental healthcare, vaccination, paediatric, eye care,
hypertension and blood sugar detection camps have been organised.The response to these
camps is so overwhelming that villagers from nearby villages throng the village school
premises where the camps are held.The earthquake, which struck Gujarat in January
2001, left a trail of death and destruction in its wake. Zydus Cadila set up a 24 hour
helpline at its headquarters responding to calls for medicines and first aid. Through this
helpline, the group distributed medicines worth Rs.1 crore as relief tos the victims of the
earthquake. It had also organised several talks by psychology experts to quell the fear
psychosis which people had to deal with in the aftermath of the quake. The group also
helped rehabilitate its employees who were affected by the earthquake by providing
interest free loans to all those whose houses were affected and helped them rebuild their
lives.

Zydus Cadila and Red Cross felicitate 500 blood donors

Zydus Cadila which has been actively promoting blood donation drive having held one
recently for its employees earlier this year, honoured 500 people who have donated their
blood for over 25, 50, 75 and 100 times. These include a record number of 28 centurion
blood donors, 6 handicaped blood donors and 11 women blood donors.
The awardees received the Zydus Red Cross Blood Donation awards from His
Excellency, Governor of Gujarat at a function held at the Tagore Hall Paldi. The function
was jointly organised by Zydus Cadila in association with Ahmedabad Red Cross
Programme.
Shri Ramanbhai Patel - AMA Centre for Excellence in Education was set up in memory
of our late Founder Chairman Shri Ramanbhai Patel in May 2001, is a tribute to his quest
for knowledge and desire to contribute to the cause of education.
This year the centre gave away the first Shrestha Shikshak award to honour the
contributions of a teacher to a child's world of learning. Nomination forms were sent out
to 2000 schools across Gujarat. We received an overwhelming response with more than
200 applications pouring in from far flung areas of Gujarat such as Kutch, Amreli,
Banaskantha, Kheda, Porbandar, Anjar, Dodhiya and Petlad. The awards committee
comprising Mr. Rajesh Mehta, President AMA, Mr. Kingshuk Nag, Editor, Times of
India, Mr. V. J. Trivedi, an emiment educationist & former Principal of Gujarat College
and Mr . P. R. Joshi Chairman, Public Relations Committee, AMA, adjudged Mr.
Natwarlal Shantilal Bhatt, a teacher from Matirala High school in Amreli district as the
Shrestha Shikshak. He received the award from the Chief Guest, Mr. P. N. Bhagawati,
Former Chief Justice of India, Member United Nations Human Rights Committee &
Chancellor Hyderabad University.
A sporty messageThe Aten -SMAG annual cricket tournament was flagged off on the
31st of August at the Gujarat College grounds in Ahmedabad . The cricket tournament
aims at creating health awareness amongst doctors and the importance of keeping fit. 20
teams consisting of doctors from different hospitals across Ahmedabad will play in the
tournament The matches will be held every Sunday beginning from 31st August to 28th
of Septmeber2003. A hypertension detection camp will also be conducted at the venue of
the match.
Cadila Healthcare Ltd.
Sales (2007-2008) =Rs.1750 crores (rounded off)
Net profit after tax =Rs.240 crores (rounded off)
CSR Budget= Not Available
Karmayog 2008 CSR Rating: 2 / 5
CSR activities:
Community
In keeping with its mission to create healthier communities globally, Zydus Cadila is
actively involved in developing the community of which it forms a part.

Through the Ramanbhai Foundation, it has undertaken initiatives in the field of

pharmaceutical research, education and healthcare. Under the aegis of the Foundation, the
group organises an International Symposium on the latest trends in Pharmaceutical
Sciences, once every two years. Three International symposia have been held so far with
more than 40 research scientists, academicians and research professionals from across the
world sharing their insights on the latest developments in pharmaceutical research.

Education
‘The Zydus School for Excellence’ – a centre for learning where young minds are free to
grow in relationship to his or her potential has also been set up under the aegis of the
Foundation. The ‘Shri Ramanbhai Patel Memorial Scholarship Programme’ jointly
funded by a grant from the Ramanbhai Foundation and Zydus School for Excellence
funds the education of students from disadvantaged backgrounds.

Shri Ramanbhai B. Patel - AMA Centre for Excellence in Education, provides a platform
for parents, teachers and students to highlight the critical educational issues of the day.
The centre conducts open house discussions, memorial lectures on excellence in
education, progressive learning programmes for academicians and knowledge sharing
forums. The centre also honours teachers for their contributions to a child’s world of
learning.

Healthcare
Dedicated to the memory of the group’s founder, the IPA – Shri Ramanbhai B. Patel
Foundation (IRF) has been jointly set up with the Indian Pharmaceutical Association. IRF
recognises and honours ‘commitment and excellence’ in the field of pharmacy.

As a part of its outreach programmes, the group organises rural healthcare camps
annually with its team of medical advisors and employees, volunteering their services. So
far, the group has organised general healthcare camps, diagnostic, dental-care, eye-care
and paediatric camps.

Through the Ramanbhai Foundation, the group also extends its support during times of
natural calamities.